| Wormwood (Artemisia absinthium) for poorly responsive early-stage IgA nephropathy: a pilot uncontrolled trial. | |
| | |
MedLine Citation:
|
PMID: 20843592 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Inhibition of the renin-angiotensin system is a widely accepted approach to treat immunoglobulin A (IgA) nephropathy, whereas the role of fish oils as a supplement is controversial. Tumor necrosis factor α (TNF-α) is considered to be involved in the pathophysiologic process of this disorder. Recent in vitro and clinical observations that wormwood can decrease TNF-α levels has led us to investigate the effect of wormwood as a supplement in patients with IgA nephropathy. STUDY DESIGN: Pilot uncontrolled trial. SETTING & PARTICIPANTS: 10 patients with biopsy-proven IgA nephropathy, normal kidney function, and a history of at least 3 months of proteinuria with protein excretion > 500 mg/d and < 3,500 mg/d despite ongoing dual renin-angiotensin system blockade. INTERVENTION: The selected patients were given supplements of 1.8 g/d of thujone-free wormwood preparation for 6 months without discontinuing their renin-angiotensin system blockade. OUTCOMES: Proteinuria and blood pressure after intervention compared with baseline values. MEASUREMENTS: Monthly assessment of urine protein-creatinine ratio and blood pressure during the observation period. RESULTS: Urine protein-creatinine ratio decreased significantly from 2,340 ± 530 to 315 ± 200 mg/g at the end of the supplementation period (P < 0.001) and was stable during the supplement-free follow-up of another 6 months. Estimated glomerular filtration rate and endogenous creatinine clearance were unchanged during the entire study period. There was a moderate, but significant, decrease (P < 0.002) in mean arterial blood pressure. LIMITATIONS: Open uncontrolled trial including a small number of patients. CONCLUSIONS: Thujone-free wormwood with its favorable safety profile can be an alternative supplement to manage proteinuria in patients with IgA nephropathy. |
| | |
Authors:
|
Simone Krebs; Bilal Omer; Talib Noor Omer; Danilo Fliser |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2010-09-16 |
Journal Detail:
|
Title: American journal of kidney diseases : the official journal of the National Kidney Foundation Volume: 56 ISSN: 1523-6838 ISO Abbreviation: Am. J. Kidney Dis. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-24 Completed Date: 2010-12-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8110075 Medline TA: Am J Kidney Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 1095-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Nuclear Medicine, University of Freiburg, Germany. simone.krebs@uniklinik-freiburg.de |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT01126931 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Artemisia absinthium* Blood Pressure / physiology Creatinine / urine Female Glomerular Filtration Rate / physiology Glomerulonephritis, IGA / drug therapy*, physiopathology, urine Humans Male Phytotherapy* Pilot Projects Plant Preparations / therapeutic use* Proteinuria / drug therapy*, physiopathology, urine Renin-Angiotensin System / physiology Treatment Outcome Tumor Necrosis Factor-alpha / physiology Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Plant Preparations; 0/Tumor Necrosis Factor-alpha; 60-27-5/Creatinine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of endothelial cell injury in thrombotic microangiopathy.
Next Document: A policy case study of blood in Australia.